A short protocol using dexamethasone and monophosphoryl lipid A generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokines.
about
Gene Expression Profiling of Human Monocyte-derived Dendritic Cells - Searching for Molecular Regulators of TolerogenicityTherapeutic Potential of Hyporesponsive CD4(+) T Cells in AutoimmunityTargeting dendritic cell function during systemic autoimmunity to restore toleranceTargeting of tolerogenic dendritic cells towards heat shock proteins: a novel therapeutic strategy for autoimmune diseases?Dexamethasone and Monophosphoryl Lipid A-Modulated Dendritic Cells Promote Antigen-Specific Tolerogenic Properties on Naive and Memory CD4+ T CellsTreatment with Dexamethasone and Monophosphoryl Lipid A Removes Disease-Associated Transcriptional Signatures in Monocyte-Derived Dendritic Cells from Rheumatoid Arthritis Patients and Confers Tolerogenic Features.Dexamethasone and Monophosphoryl Lipid A Induce a Distinctive Profile on Monocyte-Derived Dendritic Cells through Transcriptional Modulation of Genes Associated With Essential Processes of the Immune Response.Regulating Immunogenicity and Tolerogenicity of Bone Marrow-Derived Dendritic Cells through Modulation of Cell Surface Glycosylation by Dexamethasone Treatment.Co-delivery of autoantigen and dexamethasone in incomplete Freund's adjuvant ameliorates experimental autoimmune encephalomyelitis.Innate immune cells for immunotherapy of autoimmune and cancer disorders.Shuttling Tolerogenic Dendritic Cells across the Blood-Brain Barrier In Vitro via the Introduction of De Novo C-C Chemokine Receptor 5 Expression Using Messenger RNA Electroporation.Antigen Loading (e.g., Glutamic Acid Decarboxylase 65) of Tolerogenic DCs (tolDCs) Reduces Their Capacity to Prevent Diabetes in the Non-Obese Diabetes (NOD)-Severe Combined Immunodeficiency Model of Adoptive Cotransfer of Diabetes As Well As in NODTolerogenic Dendritic Cells as a Promising Antigen-Specific Therapy in the Treatment of Multiple Sclerosis and Neuromyelitis Optica From Preclinical to Clinical Trials.Searching for the Transcriptomic Signature of Immune Tolerance Induction-Biomarkers of Safety and Functionality for Tolerogenic Dendritic Cells and Regulatory Macrophages
P2860
Q26779413-4A1BD669-C420-4E74-8698-6817467F39BCQ26781243-6D8ECBA7-733C-4C77-B535-D3F5E0CE9D6FQ27687098-AD60C44A-01F7-4933-B128-1B5D019EB593Q40095092-B0656CA9-5990-48CD-A32C-BCB5066EC713Q41115639-DD70A8B9-3FC9-43B7-AE78-97BAEAED00A8Q41563600-5425E6C3-0441-464A-879B-286F5489D29FQ46267369-11AAB12D-BA14-40ED-9660-9C0410C3BEF2Q47325556-B8930D91-AEF7-4194-95AD-F79652A0616AQ47617033-1695EC68-E097-4E58-974A-40B916C4FF75Q48316500-1FD2496B-9BDC-4E1D-9BC7-02C8C490CF88Q49906660-BC90633A-F9F7-4605-B189-F28C5D469591Q50350123-F632846B-291A-4221-85BE-DA2A98D43C0DQ55258910-0B25963E-4CDF-4AA7-88B0-39A4C14F839DQ57300168-765337A2-580F-44E6-90D5-771D759021A7
P2860
A short protocol using dexamethasone and monophosphoryl lipid A generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokines.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A short protocol using dexamet ...... pacity to lymphoid chemokines.
@en
A short protocol using dexamet ...... pacity to lymphoid chemokines.
@nl
type
label
A short protocol using dexamet ...... pacity to lymphoid chemokines.
@en
A short protocol using dexamet ...... pacity to lymphoid chemokines.
@nl
prefLabel
A short protocol using dexamet ...... pacity to lymphoid chemokines.
@en
A short protocol using dexamet ...... pacity to lymphoid chemokines.
@nl
P2093
P2860
P50
P356
P1476
A short protocol using dexamet ...... apacity to lymphoid chemokines
@en
P2093
Bárbara Pesce
David Gárate
Javier Campos
Jaxaira Maggi
Juan Carlos Aguillón
Lilian Soto
Lorena Hoyos
María Carmen Molina
Milton Larrondo
Paulina García-González
P2860
P2888
P356
10.1186/1479-5876-11-128
P577
2013-05-24T00:00:00Z
P5875
P6179
1043194575